A detailed history of Marshall Wace, LLP transactions in Biogen Inc. stock. As of the latest transaction made, Marshall Wace, LLP holds 23,228 shares of BIIB stock, worth $5.32 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
23,228
Holding current value
$5.32 Million
% of portfolio
0.01%

Shares

22 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024

BUY
$212.02 - $267.71 $4.92 Million - $6.22 Million
23,228 New
23,228 $5.01 Million
Q2 2023

Aug 14, 2023

SELL
$275.25 - $318.06 $145 Million - $168 Million
-527,878 Reduced 99.05%
5,055 $1.44 Million
Q1 2023

May 15, 2023

SELL
$256.56 - $292.34 $182 Million - $208 Million
-711,217 Reduced 57.16%
532,933 $148 Million
Q4 2022

Feb 14, 2023

BUY
$252.44 - $306.72 $276 Million - $335 Million
1,093,576 Added 726.27%
1,244,150 $345 Million
Q3 2022

Nov 14, 2022

BUY
$194.69 - $268.46 $13 Million - $18 Million
66,866 Added 79.88%
150,574 $40.2 Million
Q2 2022

Aug 15, 2022

SELL
$187.54 - $223.02 $6.48 Million - $7.71 Million
-34,551 Reduced 29.22%
83,708 $17.1 Million
Q1 2022

May 16, 2022

BUY
$193.77 - $244.14 $17.6 Million - $22.2 Million
90,805 Added 330.75%
118,259 $24.9 Million
Q4 2021

Feb 14, 2022

BUY
$223.92 - $287.77 $3.59 Million - $4.61 Million
16,032 Added 140.36%
27,454 $6.59 Million
Q3 2021

Nov 15, 2021

SELL
$282.99 - $369.05 $181 Million - $236 Million
-639,898 Reduced 98.25%
11,422 $3.23 Million
Q2 2021

Aug 13, 2021

BUY
$259.0 - $414.71 $127 Million - $203 Million
488,764 Added 300.67%
651,320 $226 Million
Q1 2021

May 17, 2021

SELL
$242.95 - $284.63 $86.8 Million - $102 Million
-357,297 Reduced 68.73%
162,556 $45.5 Million
Q4 2020

Feb 16, 2021

BUY
$236.26 - $355.63 $95.3 Million - $143 Million
403,268 Added 345.9%
519,853 $127 Million
Q3 2020

Nov 16, 2020

BUY
$264.77 - $305.71 $18.3 Million - $21.2 Million
69,220 Added 146.14%
116,585 $33.1 Million
Q2 2020

Aug 13, 2020

SELL
$258.66 - $342.55 $4.39 Million - $5.82 Million
-16,987 Reduced 26.4%
47,365 $12.7 Million
Q1 2020

May 15, 2020

BUY
$268.85 - $341.04 $1.24 Million - $1.58 Million
4,630 Added 7.75%
64,352 $20.4 Million
Q4 2019

Feb 14, 2020

BUY
$220.06 - $304.07 $10.5 Million - $14.5 Million
47,816 Added 401.61%
59,722 $17.7 Million
Q1 2019

May 14, 2019

BUY
$216.71 - $338.96 $105,104 - $164,395
485 Added 4.25%
11,906 $2.81 Million
Q4 2018

Feb 14, 2019

SELL
$278.5 - $352.75 $198,849 - $251,863
-714 Reduced 5.88%
11,421 $3.44 Million
Q3 2018

Nov 14, 2018

BUY
$293.51 - $383.83 $3.56 Million - $4.66 Million
12,135 New
12,135 $4.29 Million
Q1 2018

May 15, 2018

SELL
$260.13 - $367.91 $5.3 Million - $7.49 Million
-20,356 Closed
0 $0
Q4 2017

Feb 14, 2018

BUY
$307.64 - $344.58 $3.68 Million - $4.12 Million
11,946 Added 142.05%
20,356 $6.49 Million
Q3 2017

Nov 13, 2017

BUY
$281.15 - $329.69 $2.36 Million - $2.77 Million
8,410
8,410 $2.63 Million

Others Institutions Holding BIIB

About BIOGEN INC.


  • Ticker BIIB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 144,000,992
  • Market Cap $33B
  • Description
  • Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...
More about BIIB
Track This Portfolio

Track Marshall Wace, LLP Portfolio

Follow Marshall Wace, LLP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Marshall Wace, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Marshall Wace, LLP with notifications on news.